Title |
Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials
|
---|---|
Published in |
Anais Brasileiros de Dermatologia, February 2017
|
DOI | 10.1590/abd1806-4841.20175070 |
Pubmed ID | |
Authors |
Romi Bloom, Kyle T. Amber |
Abstract |
Lamotrigine is an antiepileptic drug used for the treatment of epilepsy, bipolar disorder and numerous off-label uses. The development of rash significantly affects its use. The most concerning of these adverse reactions is Stevens-Johnson syndrome/toxic epidermal necrolysis. We performed a systematic review of randomized controlled trials using lamotrigine as a monotherapy to quantify the incidence of cutaneous reactions, particularly Stevens-Johnson syndrome/toxic epidermal necrolysis. Of a total of 4,364 papers regarding lamotrigine, 122 studies met our inclusion and exclusion criteria. In total, 18,698 patients were included with 1,570 (8.3%) of patients experiencing an adverse dermatologic reaction. The incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis was 0.04%. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Turkey | 3 | 43% |
Unknown | 4 | 57% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 86% |
Scientists | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 62 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 15% |
Other | 8 | 13% |
Student > Bachelor | 6 | 10% |
Researcher | 6 | 10% |
Student > Doctoral Student | 3 | 5% |
Other | 9 | 15% |
Unknown | 21 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 24% |
Neuroscience | 5 | 8% |
Nursing and Health Professions | 5 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Biochemistry, Genetics and Molecular Biology | 2 | 3% |
Other | 6 | 10% |
Unknown | 25 | 40% |